Internal Control Audit Report
KPMG Huazhen Audit No. 2603341
To all shareholders of China Resources BoYa Bio-Pharmaceutical Group Co., Ltd.:
In accordance with the "Guidelines for Internal Control Audits" and relevant requirements of the Chinese Certified Public Accountant Professional Standards, we have audited the effectiveness of internal controls over the financial reporting of China Resources BoYa Bio-Pharmaceutical Group Co., Ltd. (hereinafter referred to as "your company") as of December 31, 2025.